With 1H18 spine revenue growth reporting all over the board, and still without concrete consensus from companies and analysts on the state and future of the segment, I got really curious about M&A transactions in the space. What have companies done to purchase what they needed or divest what wasn't working?
Ember Therapeutics plans to divest its OP-1 bone morphogenetic protein (BMP-7) portfolio to Viscogliosi Brothers. The transaction is slated to close by 4Q18.